J&J's Janssen Gets EC OK for Expanded Use of Imbruvica

Date : 08/13/2019 @ 11:53AM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 131.27  -0.08 (-0.06%) @ 1:00AM
After Hours
Last Trade
Last $ 131.27 ◊ 0.00 (0.00%)

J&J's Janssen Gets EC OK for Expanded Use of Imbruvica

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the use of Imbruvica in two additional indications.

Janssen said Imbruvica is now approved in combination with obinutuzumab in adults with previously untreated chronic lymphocytic leukemia, and in combination with rituximab for adults with Waldenstrom's macroglobulinemia, a rare and incurable type of non-Hodgkin's lymphoma.

The European Medicines Agency's Committee for Medicinal Products for Human Use in June recommended EC approval of the expanded use of Imbruvica.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

August 13, 2019 07:38 ET (11:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.